IL133234A - מימן טרטרט של (r)--3 (n,n- דיציקלובוטיל-אמינו)--8 פלואורו-4,3 דיהידרו 1 h2- בנזופיראן-5 קרבוקסאמיד, תהליך להכנתו ותכשירי רוקחות המכילים אותו - Google Patents

מימן טרטרט של (r)--3 (n,n- דיציקלובוטיל-אמינו)--8 פלואורו-4,3 דיהידרו 1 h2- בנזופיראן-5 קרבוקסאמיד, תהליך להכנתו ותכשירי רוקחות המכילים אותו

Info

Publication number
IL133234A
IL133234A IL13323498A IL13323498A IL133234A IL 133234 A IL133234 A IL 133234A IL 13323498 A IL13323498 A IL 13323498A IL 13323498 A IL13323498 A IL 13323498A IL 133234 A IL133234 A IL 133234A
Authority
IL
Israel
Prior art keywords
fluoro
dihydro
tartrate
benzopyran
salt
Prior art date
Application number
IL13323498A
Other languages
English (en)
Other versions
IL133234A0 (en
Inventor
Hakan Nyqvist
Daniel D Sohn
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of IL133234A0 publication Critical patent/IL133234A0/xx
Publication of IL133234A publication Critical patent/IL133234A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
IL13323498A 1997-05-30 1998-05-15 מימן טרטרט של (r)--3 (n,n- דיציקלובוטיל-אמינו)--8 פלואורו-4,3 דיהידרו 1 h2- בנזופיראן-5 קרבוקסאמיד, תהליך להכנתו ותכשירי רוקחות המכילים אותו IL133234A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702066A SE510305C2 (sv) 1997-05-30 1997-05-30 Nytt salt
PCT/SE1998/000907 WO1998054166A1 (en) 1997-05-30 1998-05-15 A new salt

Publications (2)

Publication Number Publication Date
IL133234A0 IL133234A0 (en) 2001-03-19
IL133234A true IL133234A (he) 2004-05-12

Family

ID=20407187

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13323498A IL133234A (he) 1997-05-30 1998-05-15 מימן טרטרט של (r)--3 (n,n- דיציקלובוטיל-אמינו)--8 פלואורו-4,3 דיהידרו 1 h2- בנזופיראן-5 קרבוקסאמיד, תהליך להכנתו ותכשירי רוקחות המכילים אותו

Country Status (34)

Country Link
US (2) US6858645B2 (he)
EP (1) EP0984952B1 (he)
JP (1) JP3554338B2 (he)
KR (1) KR20010013127A (he)
CN (1) CN1198814C (he)
AR (1) AR012751A1 (he)
AT (1) ATE228121T1 (he)
AU (1) AU729301B2 (he)
BG (1) BG64051B1 (he)
BR (1) BR9809519A (he)
CA (1) CA2291732C (he)
DE (1) DE69809547T2 (he)
DK (1) DK0984952T3 (he)
EE (1) EE03874B1 (he)
ES (1) ES2187030T3 (he)
HK (1) HK1025575A1 (he)
HU (1) HUP0001878A3 (he)
ID (1) ID23794A (he)
IL (1) IL133234A (he)
IS (1) IS1943B (he)
MY (1) MY117960A (he)
NO (1) NO995853L (he)
NZ (1) NZ501075A (he)
PL (1) PL337181A1 (he)
PT (1) PT984952E (he)
RU (1) RU2193560C2 (he)
SE (1) SE510305C2 (he)
SK (1) SK282755B6 (he)
TR (1) TR199902926T2 (he)
TW (1) TW510899B (he)
UA (1) UA53720C2 (he)
WO (1) WO1998054166A1 (he)
YU (1) YU62499A (he)
ZA (1) ZA984486B (he)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102888D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102886D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0301796D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use II
SE0301795D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use I
EP2022110B1 (en) * 2006-05-11 2011-10-12 Johnson Controls Saft Advanced Power Solutions LLC Modular battery system
JP5163931B2 (ja) * 2007-03-08 2013-03-13 株式会社リコー 定着装置及び画像形成装置
EP2065385A1 (en) * 2007-11-28 2009-06-03 Laboratorios SALVAT, S.A. Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
CN101747305B (zh) * 2008-11-28 2014-06-18 中国医学科学院药物研究所 硝克柳胺化合物晶v型、其制法和其药物组合物与用途
MX360896B (es) * 2013-04-26 2018-11-21 Sanofi Sa Sal tartrato de la [ (s)-2-[metil-3-(2-oxo-pirrolidin-1-il)-bencen osulfonilamino]-3-(4-metil-piperazin-1-il)-3-oxo-propil) amida de acido 5-cloro-tiofeno-2-carboxilico.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616610A (en) 1989-12-22 1997-04-01 Astra Aktiebolag (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
US5420151A (en) 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
IT1282705B1 (it) 1996-02-28 1998-03-31 Recordati Chem Pharm Uso di antagonisti del recettore serotoninergico 5-ht|a per il trattamento dell'incontinenza urinaria
US5990114A (en) 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence

Also Published As

Publication number Publication date
DE69809547T2 (de) 2003-08-21
US20050085532A1 (en) 2005-04-21
NZ501075A (en) 2001-08-31
RU2193560C2 (ru) 2002-11-27
EE03874B1 (et) 2002-10-15
IL133234A0 (en) 2001-03-19
BR9809519A (pt) 2000-06-20
IS1943B (is) 2004-08-13
SE9702066D0 (sv) 1997-05-30
SE9702066L (sv) 1998-12-01
WO1998054166A1 (en) 1998-12-03
US20030109576A1 (en) 2003-06-12
ATE228121T1 (de) 2002-12-15
HUP0001878A3 (en) 2002-04-29
JP2002501527A (ja) 2002-01-15
ZA984486B (en) 1998-11-30
NO995853L (no) 2000-01-31
US6858645B2 (en) 2005-02-22
DK0984952T3 (da) 2003-02-24
CN1258290A (zh) 2000-06-28
CN1198814C (zh) 2005-04-27
EP0984952A1 (en) 2000-03-15
SK282755B6 (sk) 2002-12-03
CA2291732C (en) 2003-12-30
AR012751A1 (es) 2000-11-08
PL337181A1 (en) 2000-08-14
AU7792398A (en) 1998-12-30
KR20010013127A (ko) 2001-02-26
EE9900549A (et) 2000-06-15
NO995853D0 (no) 1999-11-29
IS5270A (is) 1999-11-24
YU62499A (sh) 2002-06-19
SK159499A3 (en) 2000-10-09
BG103949A (en) 2000-07-31
ES2187030T3 (es) 2003-05-16
DE69809547D1 (de) 2003-01-02
JP3554338B2 (ja) 2004-08-18
TW510899B (en) 2002-11-21
BG64051B1 (bg) 2003-11-28
HUP0001878A2 (hu) 2001-05-28
UA53720C2 (uk) 2003-02-17
AU729301B2 (en) 2001-02-01
SE510305C2 (sv) 1999-05-10
EP0984952B1 (en) 2002-11-20
HK1025575A1 (en) 2000-11-17
ID23794A (id) 2000-05-11
TR199902926T2 (xx) 2000-03-21
CA2291732A1 (en) 1998-12-03
MY117960A (en) 2004-08-30
PT984952E (pt) 2003-03-31

Similar Documents

Publication Publication Date Title
JP5086069B2 (ja) 重硫酸アタザナビルおよび新規形態の製造方法
CA2854549C (en) Ivabradine hydrochloride form iv
KR20180030964A (ko) 이브루티닙과 카복실산의 공결정체
JP2008509953A (ja) ４−［［（７ｒ）−８−シクロペンチル−７−エチル−５，６，７，８−テトラヒドロ−５−メチル−４−６−オキソ−２−ピペリジニル］アミノ］−３−メトキシ−ｎ−（１−メチル−４−ピペリジニル）ベンズアミドの水和物及び多形、その製造方法、並びにその薬物としての使用
RU2762181C2 (ru) Кристаллическая фумаратная соль (s)-[3,4-дифтор-2-(2-фтор-4-йодфениламино)фенил][3-гидрокси-3-(пиперидин-2-ил)азетидин-1-ил]метанона
EP0984952B1 (en) A new salt
CA3235361A1 (en) Polymorphs of the hydrochloride salt of linaprazan glurate
JP2008526836A (ja) シブトラミンの無機酸塩
JP5959617B2 (ja) オタミキサバンの安息香酸塩
KR101557832B1 (ko) (ｒ)-3-플루오로페닐-3,4,5-트리플루오로벤질카르밤산 1-아자비시클로 [2.2.2]옥트-3-일 에스테르의 안정한 결정성 염
JP2023521985A (ja) Ｓ－ピンドロールの有機酸付加塩
EP1515959B1 (en) Pharmaceutical salts of reboxetine
MXPA99010942A (en) A new salt
CZ426199A3 (cs) Nová sůl
CA3080657A1 (en) Crystalline salt of a tricyclic poly(adp-ribose) polymerase inhibitor
WO2022199707A1 (zh) 哌马色林药用盐、制备方法、含其的药物组合物及应用
TW202216726A (zh) 八氫噻吩并喹啉化合物之琥珀酸鹽及其結晶
WO2020240490A1 (en) Selective histamine h3 antagonist acid addition salts and process for the preparation thereof
KR20230092805A (ko) (2R, 3S)-2-(3-(4,5-디클로로-1H-벤조[d]이미다졸-1-일)프로필)피페리딘-3-올의 신규한 산부가염 및 결정형
CA2843773A1 (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
KR20190084250A (ko) 퀴나졸린 유도체의 염, 이의 제조 방법 및 응용

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees